Clinical applications of thrombolytic therapy

American Family Physician

Volumn 54, Issue 6, 1996, Pages 2041-2048

  Mair, Frances S ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANISTREPLASE; PLASMINOGEN ACTIVATOR; STREPTOKINASE; UROKINASE;

ARTERY DISEASE; ELECTROCARDIOGRAPHY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; MORTALITY; PATIENT SELECTION; REVIEW; STROKE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; VEIN THROMBOSIS;

BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PATIENT SELECTION; PULMONARY EMBOLISM; STREPTOKINASE; THROMBOLYTIC THERAPY;

EID: 0029846622     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Workman ML. Anticoagulants and thrombolytics: what's the difference? AACN Clin Issues 1994;5:26-35.
2. Lutomski DM, Bottorff M, Sangha K. Pharmacokinetic optimisation of the treatment of embolic disorders. Clin Pharmacokinet 1995;28:67-92.
3. Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardio (GISSI). Effectiveness of thrombolytic treatment in acute myocardial infarction. Lancet 1986;1(8564):397-402.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinasc, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction:ISIS-2. Lancet 1988;2(8607):349-60.
5. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombosis (ASSET). Lancet 1988;2(8610):525-30.
6. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988;1(8585):545-9.
7. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103-14.
8. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. N Engl J Med 1993;328:685-91.
9. Grines CL, Browne KJ, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673-9.
10. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-4.
11. Goldman L. Cost and quality of life: thrombolysis and primary angioplasty. J Am Coll Cardiol 1995;25:38S-41S.
12. Cairns JA, Fuster V, Gore J, Kennedy JW. Coronary Thrombolysis - Fourth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1995;108(4 suppl):401S-23S.
13. Canadian Consensus Conference on Coronary Thrombolysis. Recommendations. Can J Cardiol 1993;9:559-65.
14. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322 [Published erratum appears in Lancet 1994;343:742].
15. Weaver WD, Litwin PE, Martin JS, Kudenchuk PJ, Maynard C, Eisenberg MS, et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. The MITI Project Group. J Am Coll Cardiol 1991;18:657-62.
16. Grines CL, DeMaria AN. Optimal utilization of thrombolytic therapy for acute myocardial infarction: concepts and controversies. J Am Coll Cardiol 1990;16:223-31.
17. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
18. Gruppo Italiano per lo Studio della Sopravvivenza Nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336:65-71.
19. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;39:753-70.
20. Comerota AJ, Aldridge SC. Thrombolytic therapy for deep venous thrombosis: a clinical review. Can J Surg 1993;36:359-64.
21. Goldhaber SZ. Venous thrombosis: prevention, treatment, and relationship to paradoxical embolization. Cardiol Clin 1994;12:505-16.
22. Sharma GV, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980;303:842-5.
23. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995;108:335S-51S.
24. Goldhaber SZ. Contemporary pulmonary embolism thrombolysis. Chest 1995;107(1 Suppl): 45S-51S.
25. Clagett GP, Krupski WC. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 1995;108(4 Suppl):431S-43S.
26. Sherman DG, Dyken ML Jr, Gent M, Harrison JG, Hart RG, Mohr JP. Antithrombotic therapy for cerebrovascular disorders. An update. Chest 1995; 108:444S-456S.
27. American Heart Association issues management guidelines for acute ischemic stroke. Am Fam Physician 1995;51:1301-4.
28. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
29. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial-Europe Study Group. N Engl J Med 1996; 335:145-50.